GSK and Genmab Receive Accelerated Approval for Arzerra Oct 27, 2009
COPENHAGEN, Denmark and PHILADELPHIA, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab have received approval of Arzerra (ofatumumab) from the FDA for CLL that is refractory to fludarabine and alemtuzumab ... Today, GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen: - ) announced the accelerated approval of Arzerra(TM) (ofatumumab) from the U.S. Food and Drug Administration for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab ...... (Primezone Releases)
Genmab Achieves Milestone in Arzerra Collaboration Oct 27, 2009
COPENHAGEN, Denmark, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Summary: Genmab will receive a milestone payment of approximately DKK 116million from GSK for the FDA approval of Arzerra for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab ... A milestone payment of approximately DKK 116 million (approximately USD 23 million) was triggered by the FDA approval of Arzerra for the treatment of patients with chronic lymphocytic leukemia (CLL) that is... (Primezone Releases)
Affordable anti-rejection drug as effective as higher cost option Oct 15, 2009
alemtuzumab, a newer drug that costs about $1,000 per single-dose treatment and is marketed under the name CampathTM; and. rabbit antithymocyte globulin, which costs about four times more for its multidose treatment than alemtuzumab, and is marketed under the name ThymoglobulinTM. ... Though more expensive, rabbit antithymocyte globulin has generally been more commonly prescribed than alemtuzumab at Wake Forest Baptist and other transplant centers because there has been a concern that the newer... (EurekAlert!)
Strategies To Counteract Side Effects Of New MS Therapies Sep 15, 2009
Currently Natalizumab is the focal point of interest throughout the world, but that other new drugs, such as Alemtuzumab or anti-CD20 antibodies may soon follow. It is thus important that the neurologists are extremely well-informed about complications and the treatment thereof. (Science Daily)
Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy Jun 1, 2009
May 31 /PRNewswire/ -- The results of two large studies presented by researchers from the Starzl Transplant Institute at the University of Pittsburgh Medical Center demonstrated the long-term safety and efficacy of alemtuzumab induction and tacrolimus monotherapy ... Led by Dr. Henkie Tan, this group performed 200 consecutive living donor kidney transplants using a regimen of alemtuzumab pre-conditioning and tacrolimus monotherapy with subsequent weaning ... In a similar study report, Dr. Tan... (PR Newswire)
Health InfoCenter Feb 8, 2009
For more on the leukemia drug Alemtuzumab being studied for multiple sclerosis treatment. Read a new study that recommends high-dose flu shots for seniors. (WCAX.com, VT)
